ifosfamide and Granuloma, Hodgkin studies

Research Excerpts

Excerpt	Relevance	Reference
"This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients."	9.51	Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. ( André, M; Berriolo-Riedinger, A; Borel, C; Brice, P; Edeline, V; Feugier, P; Gac, AC; Gastinne, T; Ghesquières, H; Guidez, S; Le Bras, F; Morschhauser, F; Nicolas-Virelizier, E; Quittet, P; Ribrag, V; Stamatoullas, A; Vander Borght, T, 2022)
"A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation."	9.12	Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. ( Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE, 2007)
"One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i."	9.09	High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001)
"Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma."	9.08	Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995)
"Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed."	6.73	Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007)
"This phase I/II study assessed the combination of brentuximab vedotin (BV) with ifosfamide-carboplatin-etoposide (ICE) as a second-line therapy in refractory/relapsed (R/R) classical Hodgkin lymphoma (cHL) patients."	5.51	Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. ( André, M; Berriolo-Riedinger, A; Borel, C; Brice, P; Edeline, V; Feugier, P; Gac, AC; Gastinne, T; Ghesquières, H; Guidez, S; Le Bras, F; Morschhauser, F; Nicolas-Virelizier, E; Quittet, P; Ribrag, V; Stamatoullas, A; Vander Borght, T, 2022)
"15 months after initial treatment the first relapse of Hodgkin lymphoma was histologically confirmed and involvement of lymph nodes was identical with initial staging."	5.35	[Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis]. ( Konífrová, E; Móciková, H; Stríteský, J, 2009)
"Eight patients had low-grade non-Hodgkin's lymphoma (NHL), 28 had high-grade NHL, and 11 patients had Hodgkin's disease."	5.28	Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. ( Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S, 1991)
"A total of 143 patients with relapsed (n = 90), primary refractory (n = 32) and first line chemotherapy responsive (n = 21) non-Hodgkin lymphoma (NHL) and Hodgkin disease (HD) were treated with IVE (ifosphamide, etoposide and epirubicin) chemotherapy with the intent to proceed to high-dose therapy with either autologous or allogeneic transplantation, following peripheral blood stem cell mobilisation."	5.12	Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. ( Bishton, MJ; Byrne, JL; Haynes, AP; Lush, RJ; Russell, NH; Shaw, BE, 2007)
"One hundred and seven patients (61 with diffuse large B-cell non-Hodgkin's lymphomas and 46 with Hodgkin's disease) in relapse or following of primary therapy received ifosfamide 3 g/m2 i."	5.09	High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Conn, J; Culligan, D; Haynes, A; Iqbal, A; Jackson, GH; Lennard, AL; Leonard, RC; Lucraft, H; Proctor, SJ; Russel, N; Stark, A; Taylor, PR; Wood, K, 2001)
" Relapsing progressive lymphoma patients (n = 204; non-Hodgkin's lymphoma n = 166; Hodgkin's disease n = 38) were, after induction treatment with the DHAP-VIM (cisplatin, cytarabine, dexamethasone, etoposide, ifosfamide, methotrexate) regimen, randomly (2:1) assigned to the harvest of granulocyte-macrophage colony-stimulating factor-mobilized stem cells after the second DHAP course or autologous bone marrow cells before the second DHAP course."	5.09	Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. ( Croockewit, AJ; Fibbe, WE; Kingma, T; Uyl-de Groot, CA; van Agthoven, M; van Imhoff, GW; van Oers, MH; Vellenga, E; Verdonck, LF; Volkers, CP; Wijermans, PJ, 2001)
"Prolonged daily administration of oral etoposide has been reported to be active in refractory lymphoma."	5.08	Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. ( Ben-Shahar, M; Epelbaum, R; Haim, N, 1995)
"Seventy-two patients with recurrent or refractory malignant lymphoproliferative diseases were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) and concurrent mesna to prevent urothelial toxicity; 41 patients had high/intermediate-grade non-Hodgkin's lymphoma (NHL), 18 low-grade NHL/chronic lymphocytic leukemia (CLL), and 13 Hodgkin's disease (HD)."	5.07	MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. ( Brincker, H; Mirza, MR, 1991)
" Patients who proceeded to haematopoietic stem cell transplants (HDTs) received conditioning therapy with BEAM [for the Hodgkin's Lymphoma (HL) and non-Hodgkin's Lymphoma (NHL) groups], or melphalan 100 mg/m2 and mitoxantrone [for the multiple myeloma (MM) patients]."	3.73	Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. ( Albarello, A; Ballerini, F; Balocco, M; Canepa, L; Canepa, P; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Varaldo, R, 2005)
"This phase-I/phase-II study evaluated panobinostat in combination with ifosfamide, carboplatin, etoposide (P-ICE) in relapsed/refractory classical Hodgkin lymphoma."	2.87	Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. ( Claret, L; Copeland, AR; Fanale, MA; Fayad, LE; Feng, L; Fowler, N; Hagemeister, FB; Hu, B; Nastoupil, LJ; Neelapu, S; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, J; Samaniego, F; Turturro, F; Westin, JR; Younes, A, 2018)
"Around 20% of Hodgkin lymphoma (HL) patients are refractory to first-line therapy with ABVD (adriamycin-bleomycin-vinblastine-dacarbazine) or relapse after complete remission."	2.76	Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. ( Al Nawakil, C; Beranger, N; Brice, P; Brière, J; de Bazelaire, C; de Kerviler, E; Ertault, M; Franchi, P; Sibon, D; Thieblemont, C, 2011)
" Sequential dose intense ifosfamide, etoposide, carboplatin +/- rituximab was more toxic and no more effective than the same drugs given in a conventional fashion."	2.74	Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. ( Beaven, AW; Chao, N; Gabriel, DA; Garcia, RA; Gockerman, JP; Moore, DT; Rizzieri, DA; Serody, JS; Shea, TC, 2009)
"Seven treatment-related deaths due to septicemia (three), cardiac arrhythmia (one), pneumonia (one), pneumonitis (one), and toxic epidermal necrolysis (one) were observed."	2.73	Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. ( Ebeling, P; Metz, K; Moritz, T; Müller, S; Nowrousian, MR; Passon, J; Schütt, P; Seeber, S; Welt, A, 2007)
"Acute renal failure and bacterial infection occurred as non-hematologic dose limiting toxicities."	2.70	A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. ( de Magalhaes-Silverman, M; Gingrich, RD; Hayashi, M; Hohl, RJ; Lee, CK; Schlueter, A; Strauss, RG, 2002)
"Alternating COPP/ABVD and rapid alternating COPP/ABV/IMEP in combination with extended-field radiotherapy are equally effective in intermediate-stage Hodgkin's lymphoma and produce excellent long-term treatment results."	2.70	Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. ( Anselmo, AP; Brosteanu, O; Diehl, V; Doelken, G; Duehmke, E; Engert, A; Franklin, J; Georgii, A; Greil, R; Hasenclever, D; Herrmann, R; Josting, A; Kirchner, H; Koch, P; Koch, T; Lathan, B; Loeffler, M; Munker, R; Paulus, U; Pfistner, B; Pfreundschuh, M; Rueffer, U; Schalk, KP; Sieber, M; Tesch, H; Wolf, J, 2002)
" We report the use of a continuous high dose infusion of ïfosfamide at a dose of 9g/m(2) over 3 days in combination with etoposide and epirubicin followed by autologous stem cell transplant with either BEAM or Melphalan/VP16 conditioning in this difficult group."	2.69	High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. ( Angus, B; Carey, PJ; Finney, RD; Galloway, MJ; Goff, DK; Haynes, A; Jackson, GH; Lennard, AL; Leonard, RC; McQuaker, IG; Proctor, SJ; Russell, N; Taylor, PR; Windebank, K, 2000)
" There were no toxic deaths."	2.69	Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation. ( Cavenagh, JD; Eden, AG; Hughes, A; Kelsey, SM; Lamont, A; McBride, NC; Mills, MJ; Newland, AC; Ward, MC, 1999)
" In older patients (> 60 years) the dosage of idarubicin and ifosfamide was reduced to 75% in the initial cycle."	2.69	DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. ( Borchmann, P; Diehl, V; Engert, A; Münch, R; Reiser, M; Schnell, R; Straub, G; Ubelacker, R; Wilhelm, M; Wörmann, B, 1998)
"Treatment of Hodgkin's disease (HD) and non-Hodgkin lymphomas (NHL) is still unsatisfactory in patients resistant to primary therapy or those with early relapses."	2.69	[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells]. ( Adam, Z; Hájek, R; Hejlová, N; Klabusay, M; Korístek, Z; Krahulcová, E; Král, Z; Mayer, J; Müllerová, I; Navrátil, M; Penka, M; Tomíska, M; Vásová, I; Vodvárka, P; Vorlícek, J, 1998)
"Patients with untreated relapse had a 92."	2.68	The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. ( Bastion, Y; Berger, F; Brice, P; Chéron, N; Fermé, C; Gabarre, J; Lepage, E; Morel, P; Nédellec, G; Reman, O, 1995)
" However on multivariate analysis only the presence of bulky disease and of B symptoms were independent adverse factors for response and for survival."	2.67	EPIC: an effective low toxicity regimen for relapsing lymphoma. ( Ashley, S; Catovsky, D; Cunningham, D; Gore, ME; Hickish, T; Mansi, J; Nicolson, V; Roldan, A; Smith, IE, 1993)
"This type of Hodgkin lymphoma is characterized by no peripheral lymphadenopathies and has been reported to have poorer prognosis."	2.58	Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature. ( Ito, M; Ito, R; Kageyama, Y; Katayama, N; Kawakami, K; Masuya, M; Nagaharu, K; Yamaguchi, T, 2018)
"Ifosfamide has been mainly used, in combination with other drugs, as a component of salvage regimens for relapsed or primarily refractory lymphoma."	2.42	Ifosfamide in hematological malignancies of adults. ( Elice, F; Rodeghiero, F, 2003)
"Thoracic and abdominal irradiation for Hodgkin's disease was performed concomitantly with chemotherapy for the non-Hodgkin's lymphoma."	2.38	Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. ( Bergeron, C; Chatel, M; Darcel, F; Edan, C; Faivre, J; Jouan, H; Le Moine, P; Le Prise-Fleury, E; Patte, C; Tass, P, 1993)
"Treatment of disseminated Hodgkin's disease still fails in about 50 percent of the cases."	2.38	[Treatment of relapses and failures in disseminated Hodgkin's disease]. ( Bastion, Y; Coiffier, B; Tigaud, JD, 1991)
"As salvage therapy in non-Hodgkin's lymphoma (NHL), IMV-Bleo (ifosfamide, methotrexate, etoposide, bleomycin) produced a complete remission (CR) rate of 41% and seemed to be particularly effective in patients with suboptimal response to first-line treatment."	2.38	European experience with ifosfamide in lymphomas. ( Diehl, V; Schaadt, M; von Kalle, AK, 1989)
"Hodgkin lymphoma is a systemic disease that commonly involves the cervical, supraclavicular, and mediastinal lymph nodes."	1.62	Atypical involvement of central nervous system in classic Hodgkin lymphoma: a case report. ( Ahmed, S; Haider, G; Irfan, B; Raza, M, 2021)
"Of the classical Hodgkin lymphoma patients, the ORR were 72."	1.56	Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study. ( Li, J; Liu, Z; Mi, M; Wang, Y; Zhang, C; Zhang, L, 2020)
" The ifosfamide dosage was reduced to two-thirds of the original protocol."	1.43	Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. ( Arima, N; Fukunaga, A; Hyuga, M; Iwasaki, M; Kishimoto, W; Maesako, Y; Nakae, Y, 2016)
"Relapsed/refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and autologous stem cell transplantation (ASCT)."	1.43	High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. ( Aurer, I; Bašić-Kinda, S; Dotlić, S; Dujmović, D; Kralik, M; Labar, B; Mazić, S; Mitrović, Z; Nemet, D; Radman, I; Šantek, F; Sertić, D, 2016)
"Ifosfamide is a nitrogen mustard alkylating agent used as both a first-line and a salvage chemotherapeutic agent in the treatment of testicular germ cell tumors, various sarcomas, carcinomas, and some lymphomas."	1.40	Chronic Ifosfamide toxicity: kidney pathology and pathophysiology. ( Akilesh, S; Duffield, JS; Juaire, N; Smith, KD, 2014)
"More recently, a number of cases of panniculitis and subcutaneous inflammatory oedema have been described."	1.37	[Severe skin reaction with mucous membrane inflammation during MINE chemotherapy]. ( Camus, M; Guillet, G; Hainaut-Wierzbicka, E; Levillain, P; Lopez, L; Saulnier, JP, 2011)
" Primary therapies were divided into four groups: radiotherapy alone, moderately dosed COPP/ABVD-like chemotherapies for intermediate and advanced stages and BEACOPP escalated."	1.37	Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. ( Diehl, V; Engert, A; Franklin, J; Hasenclever, D; Josting, A; Loeffler, M; Scholz, M, 2011)
"Ifosfamide is an alkylating agent used in the treatment of several neoplasias."	1.36	Severe ifosfamide-induced neurotoxicity: a case report. ( Breña Atienza, J; Cabello Rodríguez, A; Cháfer Rudilla, M; Merino Alonso, J; Ramos Linares, S; Ríos Rull, P, 2010)
"15 months after initial treatment the first relapse of Hodgkin lymphoma was histologically confirmed and involvement of lymph nodes was identical with initial staging."	1.35	[Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis]. ( Konífrová, E; Móciková, H; Stríteský, J, 2009)
"Patients with hematologic or solid tumors who underwent conditioning regimen were asked to score mucositis severity daily from the first day to the tenth day of reinfusion."	1.35	Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. ( Arpaci, F; Ataergin, S; Kilic, S; Komurcu, S; Kuzhan, O; Ozet, A; Ozturk, B; Ozturk, M, 2009)
"Of the 13 cases, 5 were Hodgkin's disease (HD), and 8 were non-Hodgkin's lymphoma (NHL)."	1.33	[Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. ( Ling, JY; Sun, XF; Wang, ZH; Xia, Y; Zhen, ZJ, 2006)
"Seventeen patients had non-Hodgkin lymphoma (NHL) and 13 patients had Hodgkin disease (HD)."	1.33	IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. ( Abali, H; Barista, I; Demirkazik, F; Kansu, E; Kars, A; Koc, Y; Oyan, B; Tekin, F; Tekuzman, G; Turker, A; Uner, A, 2005)
" This observation suggests a strategy of individualized dosing adapted to hematotoxicity."	1.32	Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. ( Brosteanu, O; Diehl, V; Hasenclever, D; Loeffler, M, 2004)
"From 1991 total data collection for all Hodgkin's disease patients for this population has been in place and it has been possible to demonstrate that the overall survival for Hodgkin's disease for younger patients within this population has moved from 80% pre- 1988 to 87% post- 1988."	1.32	Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). ( Angus, B; Jackson, GH; Lennard, A; Lucraft, HL; Proctor, SJ; Taylor, PR; White, J; Windebank, K; Wood, K, 2003)
"Twelve patients with Hodgkin's disease (HD) and 38 patients with non-Hodgkin's lymphoma (NHL) were mobilized with MIME/G-CSF."	1.30	Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. ( Aurlien, E; Holte, H; Jakobsen, E; Kvalheim, G; Kvaløy, S; Pharo, A; Smeland, EB, 1998)
"Eight patients had low-grade non-Hodgkin's lymphoma (NHL), 28 had high-grade NHL, and 11 patients had Hodgkin's disease."	1.28	Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. ( Anders, CH; Moritz, T; Nagel-Hiemke, M; Niederle, N; Nowrousian, MR; Schmidt, CG; Seeber, S, 1991)
"47 patients with stages IIIB and IV Hodgkin's disease underwent laparotomy with splenectomy as restaging procedure after first-line chemotherapy (CT) which included 4 cycles of CT ABV/IMEP/PCAV/ABV."	1.28	Surgical restaging of advanced Hodgkin's disease after first line chemotherapy. ( Bourstyn, E; Brice, P; Colin, P; D'Agay, MF; Extra, JM; Fermand, JP; Fermé, C; Frija, J; Lepage, E; Miclea, JM, 1991)
"Forty-seven patients with Hodgkin's disease in relapse were treated with MIME combination chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide)."	1.27	MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. ( Cabanillas, F; Hagemeister, FB; McLaughlin, P; Riggs, S; Salvador, P; Tannir, N; Velasquez, WS, 1987)
"153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide."	1.26	[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)]. ( Hartwich, G; Lutz, H; Neidhardt, B, 1978)

Research

Studies (113)

Authors

Clinical Trials (7)

Trial Overview

Trial Outcomes

Number of Participants With Grade 3 or 4 Toxicity

Timeframe	Studies, this research(%)	All Research%
pre-1990	6 (5.31)	18.7374
1990's	26 (23.01)	18.2507
2000's	39 (34.51)	29.6817
2010's	36 (31.86)	24.3611
2020's	6 (5.31)	2.80

Authors	Studies
Ahmed, S	1
Irfan, B	1
Raza, M	1
Haider, G	1
Stamatoullas, A	2
Ghesquières, H	1
Feugier, P	1
André, M	1
Le Bras, F	1
Gac, AC	1
Borel, C	1
Gastinne, T	1
Quittet, P	1
Morschhauser, F	1
Ribrag, V	2
Guidez, S	1
Nicolas-Virelizier, E	1
Berriolo-Riedinger, A	1
Vander Borght, T	1
Edeline, V	1
Brice, P	6
Bryan, LJ	1
Casulo, C	1
Allen, PB	1
Smith, SE	1
Savas, H	1
Dillehay, GL	1
Karmali, R	1
Pro, B	2
Kane, KL	1
Bazzi, LA	1
Chmiel, JS	1
Palmer, BA	1
Mehta, J	1
Gordon, LI	1
Winter, JN	1
Marr, K	1
Ronsley, R	1
Nadel, H	1
Douglas, K	1
Gershony, S	1
Strahlendorf, C	1
Davis, JH	1
Deyell, RJ	1
Mi, M	1
Zhang, C	1
Liu, Z	1
Wang, Y	1
Li, J	1
Zhang, L	1
Phillips, EH	1
Collins, GP	1
Cwynarski, K	1
Hu, B	1
Younes, A	4
Westin, JR	1
Turturro, F	1
Claret, L	1
Feng, L	1
Fowler, N	1
Neelapu, S	1
Romaguera, J	1
Hagemeister, FB	2
Rodriguez, MA	1
Samaniego, F	2
Fayad, LE	1
Copeland, AR	1
Nastoupil, LJ	1
Nieto, Y	1
Fanale, MA	1
Oki, Y	1
Moskowitz, AJ	4
Schöder, H	2
Gavane, S	1
Thoren, KL	1
Fleisher, M	1
Yahalom, J	5
McCall, SJ	2
Cadzin, BR	1
Fox, SY	2
Gerecitano, J	2
Grewal, R	2
Hamlin, PA	2
Horwitz, SM	1
Kumar, A	2
Matasar, M	2
Ni, A	1
Noy, A	4
Palomba, ML	2
Perales, MA	2
Portlock, CS	3
Sauter, C	2
Straus, D	4
Zelenetz, AD	4
Moskowitz, CH	6
Nagaharu, K	1
Masuya, M	1
Kageyama, Y	1
Yamaguchi, T	1
Ito, R	1
Kawakami, K	1
Ito, M	1
Katayama, N	1
Ter-Ovanesov, MD	1
Valkin, DL	1
Gaboyan, AS	1
Kukosh, MY	1
Ronzin, AV	1
Andrianova, VS	1
Larin, AL	1
Zhuk, AI	1
Abuelgasim, KA	1
Alzahrani, M	1
Alsharhan, Y	1
Khairi, M	1
Hommady, M	1
Gmati, G	1
Salama, H	1
Ali, O	1
Alahmari, B	1
Masuadi, EM	1
Alaskar, A	1
Alhejazi, A	1
Damlaj, M	1
Kelly, KM	1
Cole, PD	2
Pei, Q	1
Bush, R	1
Roberts, KB	1
Hodgson, DC	1
McCarten, KM	1
Cho, SY	1
Schwartz, C	1
Eroglu, C	1
Kaynar, L	1
Orhan, O	1
Keklik, M	1
Sahin, C	1
Yildiz, OG	1
Mentes, S	1
Kurnaz, F	1
Aslan, D	1
Sivgin, S	1
Soyuer, S	1
Eser, B	1
Cetin, M	1
Unal, A	1
Akilesh, S	1
Juaire, N	1
Duffield, JS	1
Smith, KD	1
Shankar, A	1
Hayward, J	1
Kirkwood, A	1
McCarthy, K	1
Hewitt, M	1
Morland, B	1
Daw, S	1
Maruyama, D	1
Trippett, TM	1
Schwartz, CL	2
Guillerman, RP	2
Gamis, AS	1
Gardner, S	1
Hogan, S	1
London, WB	1
Chen, L	2
de Alarcon, P	1
Horwitz, S	1
Kobos, R	1
Shukla, N	1
Steinherz, P	1
Trippett, T	3
Zelenetz, A	1
Horton, TM	1
Drachtman, RA	1
McCarten, K	1
Voss, S	1
Buxton, A	1
Howard, SC	2
Hogan, SM	1
Sheehan, AM	1
López-Terrada, D	1
Mrazek, MD	1
Agrawal, N	1
Wu, MF	1
Liu, H	1
De Alarcon, PA	1
Trippet, TM	1
Esbah, O	1
Tekgündüz, E	1
Şirinoğlu Demiriz, I	1
Civriz Bozdağ, S	1
Kaya, A	1
Tetik, A	1
Kayıkçı, Ö	1
Durgun, G	1
Kocubaba, Ş	1
Altuntaş, F	1
Balzarotti, M	4
Brusamolino, E	1
Angelucci, E	1
Carella, AM	1
Vitolo, U	1
Russo, E	1
Congiu, A	1
Gotti, M	1
Massidda, S	1
Botto, B	1
Annechini, G	1
Spina, M	3
Re, A	1
Zilioli, VR	1
Merli, F	1
Salvi, F	1
Stelitano, C	1
Bonfichi, M	1
Rodari, M	1
Murru, R	1
Magagnoli, M	4
Anastasia, A	1
Mazza, R	2
Giordano, L	1
Santoro, A	5
Aurer, I	1
Nemet, D	1
Mitrović, Z	1
Dujmović, D	1
Bašić-Kinda, S	1
Radman, I	1
Sertić, D	1
Šantek, F	1
Kralik, M	1
Dotlić, S	1
Mazić, S	1
Labar, B	1
Fukunaga, A	1
Hyuga, M	1
Iwasaki, M	1
Nakae, Y	1
Kishimoto, W	1
Maesako, Y	1
Arima, N	1
Dhakal, B	1
Veltri, LW	1
Fenske, TS	1
Eastwood, D	1
Craig, MD	1
Cumpston, A	1
Shillingburg, A	1
Esselman, J	1
Watkins, K	1
Pasquini, MC	1
D'Souza, A	1
Hari, P	1
Kanate, AS	1
Hamadani, M	1
Ozturk, M	1
Komurcu, S	1
Kilic, S	1
Ozet, A	1
Arpaci, F	1
Ozturk, B	1
Kuzhan, O	1
Ataergin, S	1
Shea, TC	1
Beaven, AW	1
Moore, DT	1
Serody, JS	1
Gabriel, DA	1
Chao, N	1
Gockerman, JP	1
Garcia, RA	1
Rizzieri, DA	1
Ding, L	1
Wang, HX	1
Xue, M	1
Zhu, L	1
Liu, J	1
Yan, HM	1
Duan, LN	1
Wang, ZD	1
Persky, DO	1
Filatov, A	1
Saxena, R	1
Cui, H	1
Teruya-Feldstein, J	2
Eckrich, MJ	1
Domm, J	1
Ho, R	1
Whitlock, JA	1
Frangoul, H	1
Fernández de Larrea, C	1
Martínez, C	1
Gaya, A	1
López-Guillermo, A	1
Rovira, M	1
Fernández-Avilés, F	1
Lozano, M	1
Bosch, F	1
Esteve, J	1
Nomdedeu, B	1
Montserrat, E	1
Carreras, E	1
Móciková, H	1
Konífrová, E	1
Stríteský, J	1
Ramos Linares, S	1
Breña Atienza, J	1
Cháfer Rudilla, M	1
Ríos Rull, P	1
Cabello Rodríguez, A	1
Merino Alonso, J	1
Zhang, Z	1
Filippa, D	1
Kewalramani, T	2
Rice, RD	1
Maragulia, J	1
Vanak, J	1
Hamlin, P	1
Horowitz, S	2
O'Connor, OA	1
Portlock, C	1
Nimer, SD	2
Sandlund, JT	1
Pui, CH	1
Mahmoud, H	1
Zhou, Y	1
Lowe, E	1
Kaste, S	1
Kun, LE	1
Krasin, MJ	1
Onciu, M	1
Behm, FG	1
Ribeiro, RC	1
Razzouk, BI	1
Metzger, ML	1
Hale, GA	1
Rencher, R	1
Graham, K	1
Hudson, MM	1
Scholz, M	1
Engert, A	4
Franklin, J	2
Josting, A	2
Diehl, V	6
Hasenclever, D	4
Loeffler, M	5
Maragulia, JC	1
Vanak, JM	1
Sibon, D	1
Ertault, M	1
Al Nawakil, C	1
de Bazelaire, C	1
Franchi, P	1
Brière, J	1
de Kerviler, E	1
Beranger, N	1
Thieblemont, C	1
Camus, M	1
Hainaut-Wierzbicka, E	1
Levillain, P	1
Saulnier, JP	1
Lopez, L	1
Guillet, G	1
Fanale, M	1
Fayad, L	1
Liboon, MJ	1
Nunez, C	1
Anderlini, P	1
Popat, U	1
Ji, Y	1
Kwak, LW	1
Paris, A	1
Dib, M	1
Rousselet, MC	1
Urban, T	1
Tazi, A	1
Gagnadoux, F	1
George, B	1
Benson, W	3
Hertzberg, MS	3
Fox, AM	1
Dosoretz, AP	1
Mauch, PM	1
Chen, YH	1
Fisher, DC	1
LaCasce, AS	1
Freedman, AS	1
Silver, B	1
Ng, AK	1
Cocorocchio, E	1
Peccatori, F	1
Vanazzi, A	1
Piperno, G	1
Calabrese, L	1
Botteri, E	1
Travaini, L	1
Preda, L	1
Martinelli, G	1
Mian, M	1
Farsad, M	1
Pescosta, N	1
Casini, M	1
Cavattoni, IM	1
Deola, S	1
Cortelazzo, S	1
Kochbati, L	1
Fdhila, F	1
Belaid, I	1
Rifi, H	1
Barsaoui, S	1
Ben Romdhane, N	1
Bel Hadj Ali, Z	1
Mezlini, A	1
Oubich, F	1
Maalej, M	1
Lee, CK	1
de Magalhaes-Silverman, M	1
Hayashi, M	1
Schlueter, A	1
Strauss, RG	1
Hohl, RJ	1
Gingrich, RD	1
Crombie, C	2
Taper, J	2
Gottlieb, D	2
Bradstock, KF	2
Gisselbrecht, C	2
Mounier, N	2
Fermé, C	4
Proctor, SJ	3
Jackson, GH	3
Lennard, A	1
Angus, B	3
Wood, K	2
Lucraft, HL	1
White, J	1
Windebank, K	2
Taylor, PR	3
Zinzani, PL	1
Rodeghiero, F	1
Elice, F	1
Sieber, M	2
Tesch, H	2
Pfistner, B	2
Rueffer, U	2
Paulus, U	2
Munker, R	2
Hermann, R	1
Doelken, G	2
Koch, P	2
Oertel, J	1
Roller, S	1
Worst, P	1
Bischof, H	1
Glunz, A	1
Greil, R	2
von Kalle, K	1
Schalk, KP	2
Brosteanu, O	3
Duehmke, E	2
Georgii, A	2
Mueller, RP	1
Willich, N	1
Fischer, R	1
Hansmann, ML	1
Stein, H	1
Schober, T	1
Koch, B	1
Abali, H	2
Oyan, B	2
Koc, Y	2
Kars, A	2
Barista, I	1
Uner, A	1
Turker, A	2
Demirkazik, F	1
Tekin, F	1
Tekuzman, G	2
Kansu, E	2
Ozdemir, E	1
Clavio, M	1
Garrone, A	1
Pierri, I	1
Michelis, GL	1
Balocco, M	1
Albarello, A	1
Varaldo, R	1
Canepa, P	1
Miglino, M	1
Ballerini, F	1
Canepa, L	1
Gobbi, M	1
Zhen, ZJ	1
Sun, XF	1
Xia, Y	1
Wang, ZH	1
Ling, JY	1
Hagberg, H	3

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation[NCT02686346]	Phase 1/Phase 2	53 participants (Actual)	Interventional	2016-03-31	Completed
Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.[NCT03500133]	Phase 4	500 participants (Anticipated)	Interventional	2017-10-06	Recruiting
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma[NCT01508312]	Phase 2	46 participants (Anticipated)	Interventional	2012-01-05	Active, not recruiting
A Phase II Study of Bortezomib (Velcade, PS-341) in Combination With Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults With Refractory/Recurrent Hodgkin Disease[NCT00381940]	Phase 2	26 participants (Actual)	Interventional	2007-01-31	Completed
Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results[NCT00324467]	Phase 2	150 participants (Actual)	Interventional	2006-08-31	Active, not recruiting
IGEV +/- Bortezomib (Velcade) as Induction Before High Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma After First Line Treatment: a Randomized Phase II Trial. On Behalf of Intergruppo Italiano Linfomi[NCT00636311]	Phase 2	13 participants (Actual)	Interventional	2008-02-29	Completed
Phase I/II Trial of Yttrium-90-labeled Daclizumab (Anti-CD25) Radioimmunotherapy With High-dose BEAM Chemotherapy and Autologous Hematopoietic Stem Cell Rescue in Recurrent and Refractory Hodgkin's Lymphoma[NCT01468311]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2011-10-11	Terminated (stopped due to Poor enrollment and ability to radioconjugate Daclizumab. Neither Center for Cancer Research (CCR) or Nuclear Medicine/Radiology wanted to do the facilities upgrade and hire personnel needed to radioconjugate the drug at the Clinical Center.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Grade 3 and 4 non-hematologic toxicity during protocol therapy. The number of patients that experience CTC Version 4 grade 3 or higher non-hematologic at any time during protocol therapy (NCT00381940)
Timeframe: 4 weeks following completion of therapy

Rate of Successful PBSC Harvest

Intervention	Participants (Count of Participants)
Treatment (Ifosfamide, Vinorelbine, Bortezomib)	9

Success is defined as the ability to harvest 2x10^6 CD34+ cells/kg within 5 collection days. (NCT00381940)
Timeframe: After 2 cycles

Complete Response (CR)

Intervention	Participants (Count of Participants)
Treatment (Ifosfamide, Vinorelbine, Bortezomib)	19

CR is defined as at least 80% reduction in the sum of the products of the perpendicular diameters of each of the nodal masses or return to normal size, along with negative nuclear medicine imaging. (NCT00381940)
Timeframe: After 2 cycles of treatment

Induction Success Rate

Intervention	participants (Number)
	With CR	Without CR
Treatment (Ifosfamide, Vinorelbine, Bortezomib)	2	21

Induction success is defined as achieving CR or PR without a targeted primary toxicity. Primary toxicity includes toxic death (which is any death predominantly attributable to treatment-related toxicities or complications, occurring during or within one month of the completion of therapy), Non-hematologic grades 3 or 4 toxicities attributable to drug (with the specific exclusion of 1) Grade 3 or 4 nausea or vomiting, 2) grade 3 transaminases (AST/ALT) elevations which return to < grade 1 prior to the time of the next treatment course, 3) grade 3 or 4 fever or infection, and 4) Grade 3 mucositis.) and Hematologic toxicity (Delay of >2 weeks in the start of re-induction cycle 2 or in hematologic recovery after cycle 2 secondary to severe myelosuppression, infection, or sepsis.) (NCT00381940)
Timeframe: After 2 cycles and 4 cycles

Overall Response Rate

Intervention	Participants (Count of Participants)
	Induction Success Rate (After 2 cycles)	Induction Success Rate (After 4 cycles)
Treatment (Ifosfamide, Vinorelbine, Bortezomib)	19	12

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR (NCT00381940)
Timeframe: After 2 cycles and 4 cycles

Complete Response Rate

Intervention	Participants (Count of Participants)
	Overall Response Rate (After 2 cycles)	Overall Response Rate (After 4 cycles)
Treatment (Ifosfamide, Vinorelbine, Bortezomib)	19	12

Complete response rate is defined as the time it takes a participant to achieve a complete response. Response is assessed by the Revised Response Criteria for Malignant Lymphoma. Complete response requires all of the following: complete disappearance of all detectable clinical evidence of disease and disease related symptoms if present before therapy. A post treatment residual mass is permitted as long as it is positron emission tomography (PET) negative. If a pretreatment PET scan was negative, all lymph nodes and nodal masses must have regressed on computed tomography (CT) to normal size (<1.5 cm in their greatest transverse diameter for nodes >1.5 cm before therapy); Previously involved nodes that were 1.1 to 1.5 cm in their long axis and more than 1.0 cm in their short axis before treatment must have decreased to <1.0 cm in their short axis after treatment. (NCT01468311)
Timeframe: 20 months post autologous stem cell transplant

Disease Free Survival (DFS)

Intervention	months (Median)
Yttrium-90-labeled Daclizumab + Chemotherapy	7.5

DFS is defined as the amount of time participants remain disease free. (NCT01468311)
Timeframe: DFS is evaluated at day 100 post autologous stem cell transplant, then 1-4 times yearly for 5 years

Number of Participants With A Dose Limiting Toxicity

Intervention	months (Median)
Yttrium-90-labeled Daclizumab + Chemotherapy	36

Patients who develop either a Common Terminology Criteria in Adverse Events (CTCAE) v4.0 grade 3 or greater non-hematologic toxicity, with the exception of fatigue, of more than 5 days duration possibly, probably or definitely related to the infusion of 90Y-daclizumab prior to the start of Carmustine, Etoposide, Cytarabine, [Ara-C, Cytosine Arabinoside] and Melphalan (BEAM) chemotherapy (Day - 6) will have developed by definition a dose-limiting toxicity (DLT). (NCT01468311)
Timeframe: 30 months

Number of Participants With Adverse Events

Intervention	Participants (Count of Participants)
Yttrium-90-labeled Daclizumab + Chemotherapy	0

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01468311)
Timeframe: 30 months

Overall Survival

Intervention	Participants (Count of Participants)
Yttrium-90-labeled Daclizumab + Chemotherapy	3

Overall survival is defined as the time from the date of registration to the date of death due to any cause or if no death occurs to the last documented information on the patient. (NCT01468311)
Timeframe: OS is evaluated at day 100 post autologous stem cell transplant, then 1-4 times yearly for 5 years

Article	Year
Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature. Journal of medical case reports, 2018, May-30, Volume: 12, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Brentuximab Vedotin; C	2018
[Hepatic leiomyosarcoma: a case report]. Voprosy onkologii, 2016, Volume: 62, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Hepatectomy; Hodgkin Disease; H	2016
[Treatment strategy of gray zone lymphomas]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Burkitt Lymp	2014
Ifosfamide salvage treatment before autologous stem cell transplantation in patients with refractory and relapsed Hodgkin's lymphoma: a GELA experience. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 1 Topics: Hodgkin Disease; Humans; Ifosfamide; Salvage Therapy; Secondary Prevention; Stem Cell Transplantatio	2003
Ifosfamide, epirubicin and etoposide (IEV) in non-Hodgkin's lymphoma and Hodgkin's disease: the Italian experience. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Epirubicin; Etoposide; Hod	2003
Ifosfamide in hematological malignancies of adults. Oncology, 2003, Volume: 65 Suppl 2 Topics: Adult; Antineoplastic Agents, Alkylating; Burkitt Lymphoma; Hematologic Neoplasms; Hodgkin Disease;	2003
[Malignant lymphoma]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1994, Mar-10, Volume: 83, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide;	1994
Cerebral non-Hodgkin's lymphoma discovered when treating Hodgkin's disease. Medical and pediatric oncology, 1993, Volume: 21, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Carmustine; Cyc	1993
[Treatment of relapses and failures in disseminated Hodgkin's disease]. Presse medicale (Paris, France : 1983), 1991, Nov-02, Volume: 20, Issue:35 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplantation; Carmustine;	1991
European experience with ifosfamide in lymphomas. Seminars in oncology, 1989, Volume: 16, Issue:1 Suppl 3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Etoposide; Europe; Hodgkin Disease; Human	1989

Article	Year
Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study. Leukemia & lymphoma, 2022, Volume: 63, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carboplatin; Etoposide; Hodgkin	2022
Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial. JAMA oncology, 2023, 05-01, Volume: 9, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; Fluorodeoxygl	2023
Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma. Pediatric blood & cancer, 2020, Volume: 67, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Child; Deoxycytidine; Diseas	2020
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leukemia & lymphoma, 2018, Volume: 59, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Drug Administ	2018
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma. Bone marrow transplantation, 2019, Volume: 54, Issue:7 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Deoxycytidin	2019
Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group. British journal of haematology, 2019, Volume: 187, Issue:1 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cycl	2019
A phase I study of panobinostat in combination with ICE (Ifosfamide, Carboplatin and Etoposide) in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). Clinical advances in hematology & oncology : H&O, 2014, Volume: 12, Issue:2 Suppl 6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Hod	2014
FDG-PET adapted sequential therapy with brentuximab vedotin and augmented ICE followed by autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. Clinical advances in hematology & oncology : H&O, 2014, Volume: 12, Issue:2 Suppl 6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Brentuximab Ved	2014
Ifosfamide and vinorelbine is an effective reinduction regimen in children with refractory/relapsed Hodgkin lymphoma, AHOD00P1: a children's oncology group report. Pediatric blood & cancer, 2015, Volume: 62, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined	2015
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study. The Lancet. Oncology, 2015, Volume: 16, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carbop	2015
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study. British journal of haematology, 2015, Volume: 170, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Pres	2015
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). Leukemia & lymphoma, 2016, Volume: 57, Issue:10 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality The	2016
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. Leukemia & lymphoma, 2009, Volume: 50, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Feasibility Stu	2009
High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. British journal of haematology, 2010, Volume: 148, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Epidemiologic	2010
Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients. British journal of haematology, 2011, Volume: 153, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Dis	2011
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma. British journal of haematology, 2011, Volume: 154, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disea	2011
A pilot study on the use of outpatient fractionated ifosfamide, carboplatin and etoposide (ICE) and pegfilgrastim as a salvage and mobilizing regimen for relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Bone marrow transplantation, 2012, Volume: 47, Issue:7 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide	2012
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation. Bone marrow transplantation, 2002, Volume: 29, Issue:8 Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cy	2002
Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Com	2004
Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2005, Volume: 11, Issue:9 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies;	2005
Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combi	2006
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica, 2007, Volume: 92, Issue:1 Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fe	2007
Ifosphamide, etoposide and epirubicin is an effective combined salvage and peripheral blood stem cell mobilisation regimen for transplant-eligible patients with non-Hodgkin lymphoma and Hodgkin disease. British journal of haematology, 2007, Volume: 136, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Hematopo	2007
Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas. European journal of haematology, 2007, Volume: 78, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Combined Modality Thera	2007
IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone marrow transplantation, 2007, Volume: 40, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Deoxycytidine; Ge	2007
Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide. Cancer chemotherapy and pharmacology, 1995, Volume: 36, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cispl	1995
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:2 Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl	1995
EPIC: an effective low toxicity regimen for relapsing lymphoma. British journal of cancer, 1993, Volume: 68, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Drug A	1993
The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Th	1995
High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study. Bone marrow transplantation, 1997, Volume: 20, Issue:11 Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tran	1997
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease. Bone marrow transplantation, 1998, Volume: 21, Issue:10 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival;	1998
[Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells]. Casopis lekaru ceskych, 1998, Oct-05, Volume: 137, Issue:19 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Etopos	1998
Ifosfamide and vinorelbine: an active regimen for patients with relapsed or refractory Hodgkin's disease. British journal of haematology, 1998, Volume: 103, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Hodgkin Disease; Humans; Ifosfamide;	1998
DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Leukemia & lymphoma, 1998, Volume: 31, Issue:3-4 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dexamethas	1998
Intensive therapy with autologous stem cell transplantation as first-line therapy in poor-risk Hodgkin's disease and analysis of predictive factors of outcome. Leukemia & lymphoma, 1999, Volume: 34, Issue:3-4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Disease-Free Survival;	1999
Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation. Leukemia & lymphoma, 1999, Volume: 35, Issue:3-4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy;	1999
Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization. Bone marrow transplantation, 2000, Volume: 25, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cryopreservation; Cyc	2000
Ifosfamide, etoposide, epirubicine, and G-CSF: an effective mobilization regimen for PBSCT in heavily pretreated patients. Transplantation proceedings, 2000, Volume: 32, Issue:6 Topics: Adult; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Etoposide; Female; Granulocyte Colon	2000
High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease: a report on toxicity and efficacy. Leukemia & lymphoma, 2000, Volume: 37, Issue:5-6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirub	2000
A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood, 2001, Feb-01, Volume: 97, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Child; Cisplatin; Cyc	2001
High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Etoposide; Female; Ho	2001
High-dose ifosfamide and vinorelbine as salvage therapy for relapsed or refractory Hodgkin's disease. European journal of haematology. Supplementum, 2001, Volume: 64 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cystitis; Female; Granulocyte Colony-Stimulat	2001
Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. British journal of haematology, 2001, Volume: 114, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chi-	2001
Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Dis	2002
Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jan-15, Volume: 20, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit	2002
[Clinical experience with the cytostatic drug ifosfamide]. Die Medizinische Welt, 1977, Sep-02, Volume: 28, Issue:35 Topics: Adolescent; Adult; Aged; Bleomycin; Carcinoma; Clinical Trials as Topic; Cyclophosphamide; Drug Ther	1977
MIME combination chemotherapy in recurrent or refractory lymphoproliferative malignancies. A phase II study. Acta oncologica (Stockholm, Sweden), 1991, Volume: 30, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Hodgkin Disease; Humans; Ifo	1991

Article	Year
Atypical involvement of central nervous system in classic Hodgkin lymphoma: a case report. Journal of medical case reports, 2021, Oct-29, Volume: 15, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Hodgkin Disease; Huma	2021
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study. Medicine, 2020, Dec-04, Volume: 99, Issue:49 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deo	2020
Sequencing therapies in Hodgkin lymphoma. The Lancet. Haematology, 2021, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pr	2021
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood, 2017, 11-16, Volume: 130, Issue:20 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Carbop	2017
Contribution of involved-field radiotherapy to survival in patients with relapsed or refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. American journal of clinical oncology, 2015, Volume: 38, Issue:1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Carmustin	2015
Chronic Ifosfamide toxicity: kidney pathology and pathophysiology. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2014, Volume: 63, Issue:5 Topics: Antineoplastic Agents, Alkylating; Biopsy; Dose-Response Relationship, Drug; Drug Administration Sch	2014
Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. British journal of haematology, 2014, Volume: 165, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Chlorambuc	2014
Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE. Turkish journal of haematology : official journal of Turkish Society of Haematology, 2016, Sep-05, Volume: 33, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Do	2016
High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin's lymphoma. Annals of hematology, 2016, Volume: 95, Issue:7 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female	2016
Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients. Journal of clinical and experimental hematopathology : JCEH, 2016, Volume: 56, Issue:1 Topics: Antigens, CD34; Antineoplastic Agents; Epirubicin; Etoposide; Hematopoietic Stem Cell Mobilization;	2016
Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:10 Topics: Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Tra	2016
Self-reported experience of mucositis in cancer patients who underwent conditioning regimen and stem cell transplantation. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2009, Volume: 17, Issue:10 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carmustine; Cy	2009
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone. Leukemia research, 2009, Volume: 33, Issue:9 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Co	2009
High dose chemoradiotherapy and ASCT may overcome the prognostic importance of biologic markers in relapsed/refractory Hodgkin lymphoma. Applied immunohistochemistry & molecular morphology : AIMM, 2010, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biomarkers, Tumor; Ca	2010
Autologous stem cell transplant in a patient with Down syndrome and relapsed Hodgkin lymphoma. Pediatric blood & cancer, 2009, Dec-15, Volume: 53, Issue:7 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Child; Combined Modality Ther	2009
Salvage chemotherapy with alternating MINE-ESHAP regimen in relapsed or refractory Hodgkin's lymphoma followed by autologous stem-cell transplantation. Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:6 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Ther	2010
[Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis]. Casopis lekaru ceskych, 2009, Volume: 148, Issue:9 Topics: Deoxycytidine; Drug Eruptions; Gemcitabine; Hodgkin Disease; Humans; Ichthyosis; Ifosfamide; Male; M	2009
Severe ifosfamide-induced neurotoxicity: a case report. Pharmacy world & science : PWS, 2010, Volume: 32, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Hodgkin Disease; Humans; Ifosfamide; Male; Neurotoxicity S	2010
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Dexamethasone; Etoposide; Hodgkin Disease; Hu	2011
Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:3 Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazine	2011
Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood, 2010, Dec-02, Volume: 116, Issue:23 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modal	2010
[Severe skin reaction with mucous membrane inflammation during MINE chemotherapy]. Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Drug Eruptions; Edema; Etoposide; Female	2011
[Pulmonary Langerhans histiocytosis and Hodgkin's lymphoma]. Revue des maladies respiratoires, 2011, Volume: 28, Issue:7 Topics: Accidents, Traffic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bronchioles; Carmusti	2011
Predictive factors for radiation pneumonitis in Hodgkin lymphoma patients receiving combined-modality therapy. International journal of radiation oncology, biology, physics, 2012, May-01, Volume: 83, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplat	2012
High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors. Hematological oncology, 2013, Volume: 31, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation	2013
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation. Annals of hematology, 2013, Volume: 92, Issue:1 Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined C	2013
[Pediatric Hodgkin disease in North Tunisia: clinical and therapeutic study]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2012, Volume: 16, Issue:7 Topics: Adolescent; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cardiomyopa	2012
Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 1 Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide	2003
Strategic approach to the management of Hodgkin's disease incorporating salvage therapy with high-dose ifosfamide, etoposide and epirubicin: a Northern Region Lymphoma Group study (UK). Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14 Suppl 1 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Epirubicin; E	2003
Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease. Annals of hematology, 2004, Volume: 83, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cohort Studies; Cyclophospha	2004
IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. American journal of clinical oncology, 2005, Volume: 28, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Etoposide; F	2005
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies. Oncology reports, 2005, Volume: 14, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Carm	2005
[Clinical analysis of reactive thymic hyperplasia following chemotherapy for childhood malignant lymphoma]. Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Daca	2006
Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 4 Topics: Adolescent; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carboplati	2006
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study. American journal of hematology, 2007, Volume: 82, Issue:2 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycyti	2007
Transient global amnesia associated with the infusion of DMSO-cryopreserved autologous peripheral blood stem cells. Haematologica, 2008, Volume: 93, Issue:3 Topics: Adult; Alkalosis, Respiratory; Amnesia, Retrograde; Amnesia, Transient Global; Antineoplastic Combin	2008
Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma. Cancer investigation, 2008, Volume: 26, Issue:4 Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas	2008
Long-term survivors of malignant lymphoma patients treated with combination chemotherapy: a retrospective analysis. Japanese journal of medicine, 1984, Volume: 23, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Hodgkin Di	1984
Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood, 1995, Nov-15, Volume: 86, Issue:10 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Blood Cells; Bone Marr	1995
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease: a prospective study. European journal of haematology, 1998, Volume: 60, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Fem	1998
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone marrow transplantation, 1998, Volume: 21, Issue:9 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality The	1998
Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease. Bone marrow transplantation, 1999, Volume: 24, Issue:7 Topics: Adult; Antigens, CD34; Epirubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematop	1999
Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2. Leukemia & lymphoma, 1999, Volume: 35, Issue:5-6 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antigens, Neoplasm;	1999
High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma. Haematologica, 2000, Volume: 85, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hodgkin Disease; Humans; I	2000
Conventional salvage chemotherapy vs. high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients. Annals of hematology, 2000, Volume: 79, Issue:2 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modalit	2000
Should we always choose a nonparametric test when comparing two apparently nonnormal distributions? Journal of clinical epidemiology, 2001, Volume: 54, Issue:1 Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dat	2001
[Subcutaneous inflammatory edema induced by MINE chemotherapy]. Annales de dermatologie et de venereologie, 2001, Volume: 128, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capillary Leak Syndrome; Creatin	2001
[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)]. Medizinische Klinik, 1978, Sep-08, Volume: 73, Issue:36 Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease;	1978
Etoposide, ifosfamide, and methotrexate with or without bleomycin in refractory or recurrent lymphomas. Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2 Suppl 1 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Drug Evaluation;	1991
Surgical restaging of advanced Hodgkin's disease after first line chemotherapy. European journal of haematology, 1991, Volume: 46, Issue:5 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow; Cyclophosphamide; Dox	1991
[Thymus hyperplasia after chemotherapy in a case of Hodgkin's disease]. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin, 1991, Volume: 155, Issue:4 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Eto	1991
[Acute coronary thrombosis and myocardial ischemia following chemotherapy of Hodgkin's disease]. Onkologie, 1990, Volume: 13, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Coronary Disease;	1990
VIM-D salvage chemotherapy in Hodgkin's disease. Cancer chemotherapy and pharmacology, 1990, Volume: 27, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined M	1990
Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group. Acta oncologica (Stockholm, Sweden), 1990, Volume: 29, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Follow-Up Studies; H	1990
Salvage treatment for Hodgkin's disease in relapse. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined Modality Thera	1987
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:4 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Hematologic Di	1987

ifosfamide and Granuloma, Hodgkin